Individual generic drug information

insulin lispro

Reference monograph

Part of registered formulation

INSULIN LISPRO + INSULIN LISPRO PROTAMINE

Reference record: Insulin lispro
Source: BNF 80 (2020–2021)
Printed source pages: 776
Age groups indexed: 2

Individual active ingredientSource records are displayed separately

Some source sections could not be separated reliably in the extraction. Review the printed source pages when a field is missing or incomplete.

Overview

Extracted information for Insulin lispro only.

Indications And Dose

Diabetes mellitus ▶BY SUBCUTANEOUS INJECTION ▶Child 2–17 years: Administer shortly before meals or Endocrine system when necessary shortly after meals, according to requirements ▶Adult: Administer shortly before meals or when necessary shortly after meals, according to requirements ▶BY SUBCUTANEOUS INFUSION, OR BY INTRAVENOUS INFUSION, OR BY INTRAVENOUS INJECTION ▶Child 2–17 years: According to requirements ▶Adult: According to requirements l UNLICENSED USE ▶In children Not licensed for use in children under 2 years.

Source page 776

Prescribing And Dispensing Information

Insulin lispro is a biological medicine. Biological medicines must be prescribed and dispensed by brand name, see Biological medicines and Biosimilar medicines, under Guidance on prescribing p. 1.

Source page 776

National Funding Access Decisions

NICE decisions ▶Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (type 1) (July 2008) NICE TA151 Continuous subcutaneous insulin infusion is recommended as an option in adults and children 12 years and over with type 1 diabetes: . who suffer repeated and unpredictable hypoglycaemia, whilst attempting to achieve optimal glycaemic control with multiple-injection regimens, or . whose glycaemic control remains inadequate (HbA1c over 8.5% [69 mmol/mol]) despite optimised multiple- injection regimens (including the use of long-acting insulin analogues where appropriate). Continuous subcutaneous insulin infusion is also recommended as an option for children under 12 years with type 1 diabetes for whom multiple-injection regimens are considered impractical or inappropriate. Children on insulin pumps should undergo a trial of multiple-injection therapy between the ages of 12 and 18 years. www.nice.org.uk/guidance/ta151

Source page 776

Safety

Extracted information for Insulin lispro only.

Interactions

→Appendix 1: insulins

Source page 776

Pregnancy

Not known to be harmful—may be used during pregnancy.

Source page 776

Breast Feeding

Not known to be harmful—may be used during lactation.

Source page 776

Dose and formulations

Extracted information for Insulin lispro only.

Directions For Administration

Short-acting injectable insulins can be given by continuous subcutaneous infusion using a portable infusion pump. This device delivers a continuous basal insulin infusion and patient-activated bolus doses at meal times. This technique can be useful for patients who suffer recurrent hypoglycaemia or marked morning rise in blood-glucose concentration despite optimised multiple-injection regimens (see also NICE guidance, below). Patients on subcutaneous insulin infusion must be highly motivated, able to monitor their blood-glucose concentration, and have expert training, advice and supervision from an experienced healthcare team. ▶With intravenous use in adults For intravenous infusion give continuously in Glucose 5% or Sodium chloride 0.9%. Adsorbed to some extent by plastics of infusion set. ▶With intravenous use in children For intravenous infusion, dilute to a concentration of 0.1–1 unit/mL with Glucose 5% or Sodium Chloride 0.9% and mix thoroughly; insulin may be adsorbed by plastics, ﬂush giving set with 5 mL of infusion ﬂuid containing insulin.

Source page 776

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Solution for injection A ▶Insulin lispro (non-proprietary) Insulin lispro 100 unit per 1 ml Insulin lispro Sanofi 100units/ml solution for injection 3ml pre-filled pens | 5 pre-filled disposable injection P £25.04 DT = £29.46 Insulin lispro Sanofi 100units/ml solution for injection 3ml cartridges | 5 cartridge P £24.06 DT = £28.31 Insulin lispro Sanofi 100units/ml solution for injection 10ml vials | 1 vial P £14.12 DT = £16.61 ▶Humalog (Eli Lilly and Company Ltd) Insulin lispro 100 unit per 1 ml Humalog 100units/ml solution for injection 10ml vials | 1 vial P £16.61 DT = £16.61 Humalog 100units/ml solution for injection 3ml cartridges | 5 cartridge P £28.31 DT = £28.31 ▶Humalog Junior KwikPen (Eli Lilly and Company Ltd) Insulin lispro 100 unit per 1 ml Humalog Junior KwikPen 100units/ml solution for injection 3ml pre-filled pens | 5 pre-filled disposable injection P £29.46 DT = £29.46 ▶Humalog KwikPen (Eli Lilly and Company Ltd) Insulin lispro 100 unit per 1 ml Humalog KwikPen 100units/ml solution for injection 3ml pre-filled pens | 5 pre-filled disposable injection P £29.46 DT = £29.46 Insulin lispro 200 unit per 1 ml Humalog KwikPen 200units/ml solution for injection 3ml pre-filled pens | 5 pre-filled disposable injection P £58.92 DT = £58.92 INSULINS › INTERMEDIATE-ACTING eiiii F 751

Source page 776

Dose text by age group

Filter the extracted dose blocks for this individual drug.

Children

First line only; read the complete Indications and dose section above.

Administer shortly before meals or

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 776

Children

First line only; read the complete Indications and dose section above.

According to requirements

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 776

Age labels are extracted from the printed dose headings and require clinical review. Confirm current local guidance, dose, route, formulation, contraindications and interactions before prescribing.

Individual generic drug information

insulin lispro

Reference monograph

Part of registered formulation

INSULIN LISPRO + INSULIN LISPRO PROTAMINE

Reference record: Insulin lispro
Source: BNF 80 (2020–2021)
Printed source pages: 776
Age groups indexed: 2

Individual active ingredientSource records are displayed separately

Some source sections could not be separated reliably in the extraction. Review the printed source pages when a field is missing or incomplete.

Overview

Extracted information for Insulin lispro only.

Indications And Dose

Source page 776

Prescribing And Dispensing Information

Insulin lispro is a biological medicine. Biological medicines must be prescribed and dispensed by brand name, see Biological medicines and Biosimilar medicines, under Guidance on prescribing p. 1.

Source page 776

National Funding Access Decisions

Source page 776

Safety

Extracted information for Insulin lispro only.

Interactions

→Appendix 1: insulins

Source page 776

Pregnancy

Not known to be harmful—may be used during pregnancy.

Source page 776

Breast Feeding

Not known to be harmful—may be used during lactation.

Source page 776

Dose and formulations

Extracted information for Insulin lispro only.

Directions For Administration

Source page 776

Medicinal Forms

Source page 776

Dose text by age group

Filter the extracted dose blocks for this individual drug.

Children

First line only; read the complete Indications and dose section above.

Administer shortly before meals or

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 776

Children

First line only; read the complete Indications and dose section above.

According to requirements

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 776

Age labels are extracted from the printed dose headings and require clinical review. Confirm current local guidance, dose, route, formulation, contraindications and interactions before prescribing.